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Background: Opioid­based patient controlled analgesia (PCA) provides adequate pain control following spinal 
surgeries at the expense of increased risk of postoperative nausea and vomiting (PONV). We evaluated the efficacy 
of dexamethasone added to ramosetron, which is a newly developed five­hydroxytryptamine receptor 3 antagonist 
with a higher receptor affinity and longer action duration compared to its congeners, on preventing PONV in highly 
susceptible patients receiving opioid­based IV PCA after spinal surgery.
Methods: One hundred nonsmoking female patients undergoing spinal surgery were randomly allocated to either a 
ramosetron group (group R) or a ramosetron plus dexamethasone group (group RD)., Normal saline (1 ml) or 5 mg 
of dexamethasone was injected before anesthetic induction, while at the end of the surgery, ramosetron (0.3 mg) 
was administered to all patients and fentanyl­based IV PCA was continued for 48 hrs. The incidence and severity of 
PONV, pain score and the amount of rescue antiemetics were assessed for 48 hours after surgery.
Results: The number of patients with moderate to severe nausea (20 vs. 10, P = 0.029), and overall incidence of 
vomiting (13 vs. 5, P = 0.037) were significantly lower in the group RD than in the group R, respectively. Rescue 
antiemetic was used less in the RD group without significance.
Conclusions: Combination of ramosetron and dexamethasone significantly reduced the incidence of moderate to 
severe nausea and vomiting compared to ramosetron alone in highly susceptible patients receiving opioid­based IV 
PCA after surgery. (Korean J Anesthesiol 2012; 62: 260­265)
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Introduction
Posterior spinal surgery is usually accompanied by more 
severe postoperative pain than other neurosurgical treatments 
and therefore requires adequate pain control to enable a fast 
recovery. For that purpose, patient controlled analgesia (PCA) 
using opioids is being widely used which has been proved to 
provide high satisfaction rates for postoperative pain control 
at the expense of increased risk of postoperative nausea and 
vomiting (PONV) [1­3]. Vomiting may cause dehydration, 
electrolyte imbalance, disruption of the surgical repairs, and 
increases the perception of pain affecting patient outcome 
[4,5]. Also, increased pressure on the abdominal contents due 
to nausea and vomiting would be transmitted to the inferior 
vena cava, and then, to the epidural venous system, which 
causes increased bleeding [6]. PONV is a significant pro­
blem for neurosurgical patients affecting patient outcome 
which mandates therapies aimed at active prevention. Thus, 
recommendations for the treatment of established PONV based 
on trials in neurosurgical patients may be flawed [7]. 
Five­hydroxytryptamine receptor 3 (5­HT3) antagonists are 
the most extensively studied antiemetic agents which were 
demonstrated to possess better anti­vomiting efficacy than 
anti­nausea efficacy [8,9]. In a recent meta­ analysis, the ability 
of 5­HT3 antagonists including ondansetron and granisetron 
to prevent PONV was reported not to be satisfactory, although 
they could reduce the cumulative incidence of emesis [10]. 
Ramosetron is a newly developed 5­HT3 antagonist with 
higher receptor affinity and a longer duration of action than 
its congeners such as ondansetron and granisetron [11,12]. In 
a recent study, ramosetron demonstrated promising results 
with regard to reduction of nausea severity compared to 
ondansetron in spinal surgical patients with high susceptibility 
for developing PONV [12].
Regarding the multifactorial etiologies of PONV, combi­
nations of antiemetics from different classes could be a more 
effective antiemetic treatment modality [13], and dexametha­
sone added to 5­HT3 antagonists was reported to enhance 
antiemetic efficacy with negligible side­effects in some surgical 
setting [14,15]. However, the efficacy of dexamethasone in 
patients treated with opioid­based intravenous (IV) PCA was 
evaluated scantly and no comprehensive data exist regarding 
the antiemetic efficacy of ramosetron and dexamethasone 
following spinal surgery. The purpose of this study was to 
evaluate the efficacy of ramosetron and dexamethasone 
combi nation therapy against ramosetron alone on PONV in 
highly susceptible patients receiving opioid­based IV PCA 
after surgery in a prospective, randomized and double­blinded 
trial. 
Materials and Methods
Approval from the institutional review board and informed 
consent from patients were obtained. Before anesthesia, the 
expected risk for PONV was calculated using the simplified 
risk score system of Apfel et al. [16], which uses 4 risk factors, 
including female gender, smoking, the use of postoperative 
opioids and prior history of motion sickness or PONV. The risk 
score is constructed according to the number of significant risk 
factors in the logistic regression analysis; the presence of 0, 1, 2, 
3, or 4 of these risk factors correspond to approximately 10, 20, 
40, 60, and 80% risk for PONV, respectively. We recruited 100 
female patients, aged 18 to 65, scheduled for elective lumbar 
spinal surgery using a standard posterior approach, between 
March 2008 and January 2009. To minimize the confounding 
effect of the operation, only the patients undergoing less than 
two levels of lumbar spinal operation were studied. Basic 
inclusion criteria were nonsmoking, female patients and all 
patients were scheduled to receive IV PCA using high­dose 
opioids. The minimal expected risk for PONV was 60% in this 
study. Exclusion criteria were severe impairment of bowel 
motility, insulin­dependent diabetes mellitus, pregnancy or 
breastfeeding, administration of antiemetic medication within 
24 h before operation, systemic treatment with steroids within 
24 h before operation or during 48 h after operation, a history 
of cardiovascular or respiratory disease, active alcohol or drug 
usage, obesity (body mass index ≥ 35 kg/m2), as well as impaired 
renal and/or hepatic function. Patients with inadvertent tear of 
the dura mater during the surgery were also excluded. Patients 
were randomly allocated into either ramosetron group (group 
R, n = 50) or combination of ramosetron and dexamethasone 
group (group RD, n = 50) by a computerized randomization 
table. 
Patients were premedicated with midazolam (0.05 mg/
kg) and glycopyrrolate (0.004 mg/kg). Before the induction 
of anaesthesia, 1 ml of normal saline was injected in patients 
assigned to group R and dexamethasone (5 mg in 1 ml) was 
injected in patients assigned to group RD. Injected drugs were 
prepared in 1 ml syringes by anesthetic nurses who were not 
involved in this study. Anaesthesia was induced with 1.5-2.0 mg/
kg of propofol, and 0.5-1 μg/kg of remifentanil, and tracheal 
intubation was facilitated with 0.9 mg/kg of rocuronium. 
Patients’ lungs were mechanically ventilated with oxygen and 
air (inspired oxygen fraction 0.4), a tidal volume of 6-8 ml/kg, 
and I : E ratio of 1 : 2.0 at a respiratory rate of 8-12 breaths/min 
to maintain normocarbia throughout operation. Anaesthesia 
was maintained with continuous infusion of remifentanil 
(0.05-0.2 μg/kg/min), rocuronium (5-6 μg/kg/min), and 
sevoflurane (1.5-2.5%). At the end of the operation, all patients 
received ramosetron (0.3 mg) and PCA was initiated. The PCA 
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regimen consisted of fentanyl (25 μg/kg), ketorolac (120 mg) 
and ramosetron (0.3 mg; total volume including saline, 100 ml). 
The IV PCA was programmed to deliver 2 ml/h as background 
infusion and 1 ml per demand with a 15 min lockout for a 
48 h period. As patients were placed in the supine position, 
sevoflurane was discontinued and remifentanil was infused 
continuously at a reduced infusion rate (0.02-0.05 μg/kg/min). 
Neuromuscular blockade was antagonized with pyridostigmine 
(0.1 mg/kg) and glycopyrrolate (0.2-0.3 mg), and remifentanil 
was discontinued after extubation.
Primary efficacy variables assessed included the incidence 
and severity of nausea and incidence of vomiting in the first 48 
h following emergence from general anaesthesia. Secondary 
efficacy variables included use of additional antiemetic rescues, 
pain intensity and medication­associated complications. These 
variables were assessed by two investigators who were blinded 
to treatment group. Evaluations were performed at the following 
4 time periods: during the stay in the recovery room and in 
the ward at approximately 6 h, 6-24 h, and 24-48 h. Nausea 
was defined as subjectively unpleasant sensation associated 
with awareness of the urge to vomit and an emetic episode was 
defined as a single episode of vomiting (the forceful expulsion 
of gastric contents through the mouth). Retching, which was 
considered as vomiting, was defined as an expulsive movement 
of the stomach muscles when no stomach contents were 
expelled. The intensity of nausea was graded on verbal rating 
scales (VRS) using an 11 point scale, with 0 = no nausea to 
10 = worst possible nausea. The severity of nausea was graded 
on VRS: mild (1-3), moderate (4-6), and severe (7-10). Pain 
intensity scores were measured using a visual analog scale 
(VAS) that ranged from 0 mm (no pain) to 100 mm (worst pain 
imaginable). Rescue antiemetic therapy (metoclopromide 10 
mg, IV) was given at the discretion of the attending physicians, 
who were blinded to the patients’ group, in response to nausea, 
vomiting or at the patient’s request. IV PCA was discontinued 
when severe nausea persisted and/or upon patient’s request 
after 2 consecutive boluses of metoclopromide. The patients 
were allowed to receive ketorolac (30 mg, IV) if they complained 
of pain ≥ 50 mm on VAS. The most frequently reported side 
effects of the 5­HT3 antagonists used in conjunction with 
opioid­based IV PCA such as headache, dizziness, drowsiness, 
constipation, flushing, heat and general weakness were also 
assessed during the study period. 
Statistical analysis
Sample size estimation was performed in accordance with 
the results of a study comparing the effect of ondansetron with 
dexamethasone on PONV in a high risk group of patients [13]. 
Forty­three patients per group was determined to be adequate 
to demonstrate a 28% reduction in the incidence of PONV (from 
47% to 19%) with an at α = 0.05 and β = 0.8. Statistical analyses 
were performed with SPSS 13.0 (SPSS Inc., Chicago, IL, USA). 
All data are expressed as means (SD), number or median 
(interquartile range). Data between the groups were compared 
using a Chi­square test, Fisher’s exact test, independent t­test or 
the Mann­Whitney U test, as appropriate. A P value of less than 
0.05 was considered statistically significant. 
Results
Patient characteristics including history of PONV and/or 
motion sickness as well as operative data were similar between 
the groups (Table 1). Sixteen patients in each group had 4 
risk factors and the remaining patients had 3 risk factors for 
PONV. Operations performed were lumbar laminectomy in 
23 and 21 patients, and lumbar spinal fusion in 27 and 29 
patients in the R and RD groups, respectively. None of the 
patients had inadvertent tears of the dura mater. PCA pumps 
were discontinued in one patient each in both groups due to 
Table 1. Patient Characteristics
Group R
(n = 50)
Group RD
(n = 50)
P value
Age (yr)
Body mass index (kg/m2)
Surgery time (min)
Anesthesia time (min)
Amount of fentanyl used (μg)
History of PONV
History of motion sickness
Simplified risk score
    3 
    4
 48.8 ± 12.3
23.5 ± 2.9
112.4 ± 46.2
149.0 ± 52.9
1,384.0 ± 159.5
6
13
34 (68)
16 (32)
49.8 ± 9.2
24.2 ± 2.6
124.7 ± 51.8
166.9 ± 56.2
1,360.0 ± 144.3
1
16
34 (68)
16 (32)
0.626
0.220
0.213
0.104
0.432
0.111
0.507
Values are expressed as means ± SD or number of patients. Group R: ramosetron only, Group RD: combination of ramosetron and dexame-
thasone, PONV: postoperative nausea and vomiting.
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intractable nausea and/or vomiting.
The overall incidence of nausea was 52% in group R and 44% 
in group RD. Although the median of the highest VRS scores 
of nausea intensity during study period was similar between 
the groups, the number of patients with moderate to severe 
nausea was significantly lower in the RD group (P = 0.029). 
The difference was more prominent early in the postoperative 
period. The overall incidence of vomiting was significantly 
lower in the group RD than in the group R (P = 0.037; Table 2). 
Pain scores assessed up to 48 h after surgery were similar 
between the groups (Table 3). 
No patient was withdrawn from the study due to adverse 
events associated with antiemetic medications. The number of 
patients who experienced antiemetics­related adverse events 
during postoperative period was similar between the groups. 
There were no side effects such as increased risk of infection 
and wound dehiscence associated with the use of a single dose 
of dexamethasone (Table 4). 
Table 2. Incidence of Nausea, Vomiting, and Requirement for Rescue Antiemetic Treatment
Group R
(n = 50)
Group RD
(n = 50)
P value
PONV 
Nausea frequency/intensity
    RR
    0-6 hr
    6-24 hr
    24-48 hr
Nausea ≥ VRS 4
    RR 
    0-6 hr
    6-24 hr 
    24-48 hr 
Vomiting
    RR
    0-6 hr
    6-24 hr
    24-48 hr
Rescue antiemetic 
    RR
    0-6 hr
    6-24 hr
    24-48 hr
29 (58)
 26 (52)/ 1 [0-5]*
5 (10)
21 (42)/0 [0-0]
19 (38)/0 [0-5]
 14 (28)/0 [0-1.5]
20 (40)
2 (4)
16 (32)
12 (24)
 7 (14)
13 (26)
1 (2)
 8 (16)
 7 (14)
3 (6)
22 (44)
2 (4)
13 (26)
13 (26)
 5 (10)
24 (48)
 22 (44)/0 [0-3]*
6 (12)
15 (30)/0 [0-2]
 17 (34)/1 [0-1.5]
13 (26)/1 [0-1]
10 (20)
0
7 (14)
6 (12)
4 (8)
5 (11)
0
3 (6)
3 (6)
1 (2)
14 (28)
2 (4)
6 (12)
7 (14)
4 (8)
0.316
0.423/0.239
0.521
0.184/0.124
0.732/0.521
0.821/0.684
0.029†
0.124
0.032†
0.118
0.338
0.037†
0.367
0.102
0.318
0.617
0.096
0.622
0.066
0.147
1.000
Values are expressed as number (%) or median [interquatile range]. Group R: ramosetron only, Group RD: combination of ramosetron and 
dexamethasone, PONV: total number of patients who experienced nausea or vomiting during study period, RR: recovery room, Intensity of 
nausea was graded using VRS, VRS: verbal rating scale. *Median of the highest verbal rating scores of nausea intensity during study period, 
†Indicates a significant difference between the two groups.
Table 3. Pain Intensity Scores 
Group R
(n = 50)
Group RD
(n = 50)
P value
Pain scores
    RR
    0-6 hr
    6-24 hr
    24-48 hr
21.7 ± 20.7
40.6 ± 27.5
30.0 ± 24.7
32.7 ± 21.7
29.7 ± 19.6
36.0 ± 18.6
34.5 ± 20.1
27.6 ± 18.1
0.092
0.336
0.365
0.416
Values are expressed as means ± SD. Group R: ramosetron only, 
Group RD: combination of ramosetron and dexamethasone, RR: re-
covery room.
Table 4. Side Effects of Antiemetic Drugs and Surgery-related Com-
pli cations
Group R
(n = 50)
Group RD
(n = 50)
P value
Headache
    0-6 h
    6-24 h
    24-48 h
Dizziness
    0-6 h
    6-24 h
    24-48 h
Drowsiness
    0-6 h
    6-24 h
    24-48 h
Constipation
Total adverse event of antiemetics
Surgery-related complication
    Wound dehiscence
    Fever (> 38oC)
    Leukocytosis (> 104/μl)
3 (6)
6 (12)
6 (12)
5 (10)
7 (14)
6 (12)
3 (6)
3 (6)
1 (2)
1 (2)
22 (44)
0
7 (14)
5 (10)
3 (6)
4 (8)
4 (8)
5 (10)
4 (8)
5 (10)
1 (2)
2 (4)
3 (6)
1 (2)
17 (34)
0
2 (4)
10 (20)
1.000
0.741
0.505
1.000
0.356
0.749
0.362
1.000
0.617
1.000
0.386
1.000
0.159
0.161
Values are expressed as number (%). Group R: ramosetron only, 
Group RD: combination of ramosetron and dexamethasone.
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Discussion
In this prospective, randomized study comparing the 
effi cacies of ramosetron with that of ramosetron plus dexa­
methasone for preventing fentanyl­based IV PCA­related PONV 
in highly susceptible patients undergoing spinal surgery, the 
combination of ramosetron and dexamethasone significantly 
reduced the incidence of moderate to severe nausea and 
vomiting compared to those of ramosetron alone, although the 
incidence of total PONV was similar between the groups. 
Inadequate treatment of postoperative pain and PONV may 
result in adverse physical and psychological outcomes [17], and 
PONV may increase patient’s discomfort and also increase costs 
and unwarranted side effects [18]. 
5­HT3 antagonists are the most commonly used antiemetic 
agents for the prevention of PONV. However, previously reported 
results about their effects on preventing PONV were not 
satisfactory [4,19]. It seemed to be associated with the fact that 
5­HT3 antagonists possess better antivomiting than antinausea 
efficacy [8,9]. In our previous study [12], the incidence of PONV 
was 60-70% in patients with multiple risk factors for PONV 
in spite of ondansetron or ramosetron administration. The 
need for more effective antiemetic therapy is thus increasing 
and the limited efficacy of single anti emetics treatment has 
prompted evaluation of combination of antiemetic drugs acting 
at different receptor sites to prevent PONV [20]. Because of 
the multifactorial etiology of PONV, there has been increasing 
interest in using a combination of antiemetics from different 
classes for PONV prophylaxis. The antiemetic efficacy of 
combination of dexamethasone with earlier serotonin receptor 
antagonists such as ondansetron, granisetron and dolasetron 
was reported to be beneficial for reducing the incidence of PONV 
in several studies [14,21­23]. Hypotheses for why there is a better 
effect of combination therapy are as follows: 1) corticosteroids 
may reduce the levels of serotonin in neural tissue by depleting 
its precursor tryptophan 2) antiinflammatory properties of 
corticosteroids may prevent the release of serotonin in the 
gut 3) dexamethasone may potentiate the main effect of other 
antiemetics by sensitizing the pharmacological receptor 
[21,24,25]. Addition of dexamethasone to 5­HT3 antagonist 
reduced the incidence of PONV [14] or improved quality of 
recovery, resulting in greater satisfaction for the management of 
PONV [23] compared to 5­HT3 antagonists alone. However, little 
evaluation for the efficacy of combination of dexamethasone 
and 5­HT3 antagonist in patients treated with opioid based PCA 
has been performed [26]. 
Ramosetron is a newly developed 5­HT3 antagonist with a 
higher affinity and longer duration of action than that of the 
previously developed 5­HT3 antagonists such as ondansetron, 
granisetron and tropisetron [11,12]. The effect of dexamethasone 
added to ramosetron in patients using opioid­based IV PCA 
with high susceptibility for PONV was evaluated first in this 
study and several beneficial effects could be demonstrated. 
The combination of ramosetron and dexamethasone could 
significantly reduce the incidence of moderate to severe nausea 
and vomiting compared to ramosetron alone. In addition, there 
was a trend toward less use of rescue antiemetic agents in the 
combination group. The finding that the incidence of moderate 
to severe nausea was significantly lower in the combination 
group seems to be promising considering that moderate to 
severe nausea comes just before vomiting and that it is vomiting 
which causes dehydration, disruption of the surgical repair, and 
increases the perception of pain [4,5]. 
Total incidence of PONV, however, was not different between 
the groups and still half of the patients developed PONV 
even with combination therapy in this study. In a large trial 
to compare the efficacy of six antiemetic interventions and 
their combinations [27], increasing the number of antiemetics 
reduced the relative risk by 26%, where as the degree of risk 
reduction with dexamethosone was about 18% in this study. 
The still higher incidence of PONV in the current study might 
be associated with high dose fentanyl in the IV PCA. In contrast 
to that large amount of fentanyl continuously infused for 48 
h in this study, small boluses of opioids were intermittently 
administered at the discretion of the anesthesiologists in a 
previous study [28]. In addition, longer duration of observation 
for PONV lasting 48 h could also be responsible for the relatively 
higher incidence of PONV in this study compared to that of 
previous studies in which patients were mostly observed only 
for 24 h postoperatively. And total IV anesthesia with propofol 
or neuraxial analgesia also may be helpful in lowering the 
incidence of relatively high rates of PONV [7,28].
A limitation of this study is as follows: the minimum effective 
dose of dexamethasone to reduce the incidence of PONV when 
combined with ondansetron has been reported to be 4 mg in 
patients undergoing gynecological laparoscopy [21]. Moreover, 
cautious use of dexamethasone is recommended in surgical 
patients due to the concerns about surgery­related side effects, 
such as delayed wound healing and increased incidence of 
wound infection. Yet, evidence with regard to the appropriate 
dose of dexamethasone as an adjunct to prevent opioid based 
IV PCA related PONV has been limited and although beneficial 
effects could be demonstrated, the chosen dose in the current 
trial may be relatively small. 
Combination of ramosetron and dexamethasone signifi­
cantly reduced the incidence of moderate to severe nausea 
and vomiting compared to ramosetron alone, although the 
overall incidence of PONV was similar in both groups in highly 
susceptible patients for PONV using fentanyl­based IV PCA 
following spinal surgery using volatile anesthetics.
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